skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Critical appraisal of denosumab in the treatment and prevention of postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation

Review

(1185) Views  (560) Full article downloads

Authors: David L Kendler, Kenneth Shawn Davison

Published Date September 2010 Volume 2010:2 Pages 49 - 69
DOI: http://dx.doi.org/10.2147/ORR.S6124

David L Kendler1, Kenneth Shawn Davison2
1Prohealth Clinical Research, University of British Columbia, Vancouver, British Columbia, Canada; 2Department of Medicine, Division of Immunology and Rheumatology, Laval University, Quebec, Canada

Abstract: Antiresorptive therapies are the mainstay for treating patients with excessively high rates of bone resorption. The receptor activator of nuclear factor-κB (RANK) ligand (RANKL), secreted by osteoblasts, binds to the RANK receptor on the surface of preosteoclasts and osteoclasts to elicit osteoclast formation, survival, and activity. Osteoprotegerin, also secreted by the osteoblast, acts as a decoy RANK receptor reducing RANKL binding to RANK and reducing bone resorption. Denosumab, a fully human monoclonal antibody, has a high affinity and specificity for RANKL. Denosumab rapidly decreases bone resorption and increases bone mineral density (BMD) at the lumbar spine, total hip, femoral neck, and one-third radius sites. In head-to-head trials, denosumab increased BMD and decreased bone resorption to a significantly greater degree than alendronate. In postmenopausal osteoporotic women, denosumab decreased the risk of vertebral fracture (68%), nonvertebral fracture (20%), and hip fracture (40%) over 36 months, compared to placebo. In patients with iatrogenic hypogonadism, denosumab rapidly decreased markers of bone resorption and increased BMD. In men treated with GnRH agonist for prostate cancer, treatment with denosumab led to a 62% decreased risk of new vertebral fracture over 3 years, as compared to placebo. In all trials completed to date, comparable adverse events have been observed in both denosumab and placebo or treatment groups.

Keywords: medication adherence, fracture, bone mineral density, bone turnover markers






Readers of this article also read:

Update on bazedoxifene: A novel selective estrogen receptor modulator
Treating postmenopausal osteoporosis in women at increased risk of fracture – critical appraisal of bazedoxifene: a review
Comparison of avian and nonavian hyaluronic acid in osteoarthritis of the knee
Bisphosphonate-induced femoral fragility fractures: What do we know?
Update on the management of Dupuytren’s contracture
Genetics of osteoporotic fracture
Peroneal island flap for wound coverage in complex injuries of the lower extremity
Subclinical infection associated with delayed union after transtrochanteric rotational osteotomy
Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy
Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio